Tris Pharma Reveals Strong Safety and Efficacy Data for Cebranopadol, a New Pain Therapy

Tris Pharma, Inc., a biopharmaceutical company specializing in ADHD, pain, addiction, and neurological disorders, has announced new clinical data showcasing that cebranopadol, a dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist, causes significantly less respiratory depression…

Read MoreTris Pharma Reveals Strong Safety and Efficacy Data for Cebranopadol, a New Pain Therapy

Advanced Sterilization Products and PENTAX Medical Gain FDA Clearance for New Duodenoscope Sterilization Cycle

Advanced Sterilization Products (ASP), a division of Fortive (NYSE: FTV), and PENTAX Medical, a division of HOYA, are excited to announce FDA clearance for the new ULTRA GI™ Cycle. This innovative cycle is integrated into the STERRAD™ 100NX Sterilizer with…

Read MoreAdvanced Sterilization Products and PENTAX Medical Gain FDA Clearance for New Duodenoscope Sterilization Cycle

Eyedaptic Launches EYE6 with Ivy: AI-Powered Visual Assistant for Macular Degeneration

Eyedaptic, a leader in vision-enhancement technology, has introduced the EYE6 with Ivy, an advanced wearable vision aid featuring an AI-powered visual assistant. This next-generation smart glasses product is designed to assist individuals with age-related macular degeneration (AMD) and other retinal…

Read MoreEyedaptic Launches EYE6 with Ivy: AI-Powered Visual Assistant for Macular Degeneration

Alzamend Neuro and Mass General Launch Phase II Trial for AL001 in Alzheimer’s Disease

Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced a partnership with Massachusetts General Hospital (Mass General). Mass General will serve as…

Read MoreAlzamend Neuro and Mass General Launch Phase II Trial for AL001 in Alzheimer’s Disease

Amylyx Pharmaceuticals Gets EU Orphan Drug Status for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the European Commission has granted Orphan Drug Designation to AMX0035, its proprietary fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for treating Wolfram syndrome. This designation follows a positive opinion from…

Read MoreAmylyx Pharmaceuticals Gets EU Orphan Drug Status for AMX0035 in Wolfram Syndrome

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company specializing in innovative treatments for neurological diseases, has announced the grant of inducement awards to two new employees. The Compensation Committee of Longboard’s Board of Directors approved non-qualified stock options to…

Read MoreLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)